vs

Side-by-side financial comparison of AMREP CORP. (AXR) and Beta Bionics, Inc. (BBNX). Click either name above to swap in a different company.

Beta Bionics, Inc. is the larger business by last-quarter revenue ($27.6M vs $14.6M, roughly 1.9× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs -79.3%, a 100.8% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs 56.6%).

AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.

Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.

AXR vs BBNX — Head-to-Head

Bigger by revenue
BBNX
BBNX
1.9× larger
BBNX
$27.6M
$14.6M
AXR
Growing faster (revenue YoY)
AXR
AXR
+37.2% gap
AXR
93.8%
56.6%
BBNX
Higher net margin
AXR
AXR
100.8% more per $
AXR
21.6%
-79.3%
BBNX

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
AXR
AXR
BBNX
BBNX
Revenue
$14.6M
$27.6M
Net Profit
$3.1M
$-21.9M
Gross Margin
59.5%
Operating Margin
20.6%
-47.4%
Net Margin
21.6%
-79.3%
Revenue YoY
93.8%
56.6%
Net Profit YoY
338.9%
23.6%
EPS (diluted)
$0.58
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXR
AXR
BBNX
BBNX
Q1 26
$14.6M
$27.6M
Q4 25
$9.4M
$32.1M
Q3 25
$17.9M
$27.3M
Q2 25
$11.2M
$23.2M
Q1 25
$7.5M
$17.6M
Q4 24
$11.9M
Q3 24
$19.1M
Q2 24
$19.5M
Net Profit
AXR
AXR
BBNX
BBNX
Q1 26
$3.1M
$-21.9M
Q4 25
$1.2M
$-13.5M
Q3 25
$4.7M
$-14.2M
Q2 25
$3.9M
$-16.9M
Q1 25
$717.0K
$-28.7M
Q4 24
$4.0M
Q3 24
$4.1M
Q2 24
$4.1M
Gross Margin
AXR
AXR
BBNX
BBNX
Q1 26
59.5%
Q4 25
59.0%
Q3 25
55.5%
Q2 25
53.8%
Q1 25
50.9%
Q4 24
Q3 24
Q2 24
Operating Margin
AXR
AXR
BBNX
BBNX
Q1 26
20.6%
-47.4%
Q4 25
11.9%
-50.2%
Q3 25
34.4%
-62.5%
Q2 25
31.7%
-85.5%
Q1 25
5.7%
-105.7%
Q4 24
26.4%
Q3 24
26.1%
Q2 24
23.9%
Net Margin
AXR
AXR
BBNX
BBNX
Q1 26
21.6%
-79.3%
Q4 25
12.8%
-41.9%
Q3 25
26.3%
-52.1%
Q2 25
34.8%
-72.6%
Q1 25
9.5%
-162.5%
Q4 24
33.9%
Q3 24
21.3%
Q2 24
21.2%
EPS (diluted)
AXR
AXR
BBNX
BBNX
Q1 26
$0.58
$-0.49
Q4 25
$0.22
$-0.16
Q3 25
$0.87
$-0.33
Q2 25
$0.73
$-0.39
Q1 25
$0.13
$-0.93
Q4 24
$0.75
Q3 24
$0.76
Q2 24
$0.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXR
AXR
BBNX
BBNX
Cash + ST InvestmentsLiquidity on hand
$50.0M
$199.5M
Total DebtLower is stronger
$21.0K
Stockholders' EquityBook value
$139.4M
$271.2M
Total Assets
$143.9M
$304.4M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXR
AXR
BBNX
BBNX
Q1 26
$50.0M
$199.5M
Q4 25
$44.6M
$219.1M
Q3 25
$48.9M
$228.7M
Q2 25
$39.5M
$249.7M
Q1 25
$36.9M
$231.5M
Q4 24
$40.1M
Q3 24
$40.4M
Q2 24
$29.7M
Total Debt
AXR
AXR
BBNX
BBNX
Q1 26
$21.0K
Q4 25
$23.0K
Q3 25
$25.0K
Q2 25
$26.0K
Q1 25
$29.0K
Q4 24
$32.0K
Q3 24
$34.0K
Q2 24
$35.0K
Stockholders' Equity
AXR
AXR
BBNX
BBNX
Q1 26
$139.4M
$271.2M
Q4 25
$136.0M
$287.6M
Q3 25
$134.7M
$294.8M
Q2 25
$130.0M
$301.6M
Q1 25
$126.0M
$313.8M
Q4 24
$125.1M
Q3 24
$122.2M
Q2 24
$118.0M
Total Assets
AXR
AXR
BBNX
BBNX
Q1 26
$143.9M
$304.4M
Q4 25
$140.1M
$328.7M
Q3 25
$140.7M
$330.0M
Q2 25
$133.8M
$330.0M
Q1 25
$128.9M
$338.0M
Q4 24
$129.1M
Q3 24
$127.0M
Q2 24
$122.8M
Debt / Equity
AXR
AXR
BBNX
BBNX
Q1 26
0.00×
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXR
AXR
BBNX
BBNX
Operating Cash FlowLast quarter
$5.4M
Free Cash FlowOCF − Capex
$5.4M
FCF MarginFCF / Revenue
37.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$20.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXR
AXR
BBNX
BBNX
Q1 26
$5.4M
Q4 25
$-4.3M
$-8.6M
Q3 25
$9.5M
$-8.7M
Q2 25
$10.2M
$-13.6M
Q1 25
$-3.2M
$-20.0M
Q4 24
$-182.0K
Q3 24
$10.7M
Q2 24
$10.7M
Free Cash Flow
AXR
AXR
BBNX
BBNX
Q1 26
$5.4M
Q4 25
$-4.3M
$-10.5M
Q3 25
$9.5M
$-10.0M
Q2 25
$9.7M
$-15.4M
Q1 25
$-3.3M
$-20.3M
Q4 24
$-268.0K
Q3 24
$10.7M
Q2 24
$10.3M
FCF Margin
AXR
AXR
BBNX
BBNX
Q1 26
37.0%
Q4 25
-45.9%
-32.8%
Q3 25
53.2%
-36.7%
Q2 25
86.4%
-66.2%
Q1 25
-43.4%
-115.1%
Q4 24
-2.3%
Q3 24
55.8%
Q2 24
52.5%
Capex Intensity
AXR
AXR
BBNX
BBNX
Q1 26
0.1%
Q4 25
0.6%
5.9%
Q3 25
0.1%
4.7%
Q2 25
5.2%
7.7%
Q1 25
0.3%
1.9%
Q4 24
0.7%
Q3 24
0.2%
Q2 24
2.3%
Cash Conversion
AXR
AXR
BBNX
BBNX
Q1 26
1.72×
Q4 25
-3.54×
Q3 25
2.03×
Q2 25
2.63×
Q1 25
-4.51×
Q4 24
-0.05×
Q3 24
2.63×
Q2 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons